Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lantern Pharma, Inc. (LTRN)
NASDAQ:LTRN
Lantern Pharma (LTRN) Stock Price & Analysis
210 Followers
LTRN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.38 - $11.99
Previous Close$6.33
Volume12.82K
Average Volume (3M)351.83K
Market Cap
$69.29M
Enterprise Value$27.04M
Total Cash (Recent Filing)$41.30M
Total Debt (Recent Filing)$234.47K
Price to Earnings (P/E)-3.9
Beta1.16
Next Earnings
Aug 06, 2024EPS Estimate
-$0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding10,758,805
10 Day Avg. Volume126,157
30 Day Avg. Volume351,827
Standard Deviation0.22
R-Squared0.13
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.63
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-3.67
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Lantern Pharma News
PremiumCompany Announcements
Lantern Pharma Announces Fiscal Year and Q4 Results Webinar
Bulls Say, Bears Say
Bulls Say
Clinical Trial AdvancementsEnrollment for the Harmonic Phase 2 study is progressing in the US and Asia, which may expedite the trial process and lead to quicker clinical results.
Potential Drug EfficacyLP-184 has not only demonstrated the ability to penetrate the blood-brain barrier but also shown promising bioavailability in the brain in preclinical studies, indicating potential for effective treatment options.
Strategic Clinical ExpansionThe approval to expand the Harmonic study into Asia represents a strategic move to increase the study population, potentially accelerating the development timeline and patient access to innovative treatments.
Bears Say
Clinical TrialsEnrollment in the Harmonic study has been slow, potentially affecting the study's timeline.
Drug Development ExpectationsThe company's expectation to see a doubling in OS benefit from the study is viewed as an aggressive goal.
Supply IssuesThere is a shortage of platinum chemotherapy which has impacted enrollment of clinical trials.
---
Ownership Overview
25.11% Insiders
4.32% Mutual Funds
5.80% Other Institutional Investors
64.78% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $2.38 and its highest was $11.99 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Currently, no data Available
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 06, 2024 which is in 81 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 09, 2024. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.43 by -$0.08.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Overvalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -$0.56.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 10,758,805 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.43. Following the earnings report the stock price went down -9.545%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Among the largest hedge funds holding Lantern Pharma, Inc.’s share is Carlson Capital LP. It holds Lantern Pharma, Inc.’s shares valued at 257K.
---
Lantern Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
LTRN Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 35.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 11.9%
Last 30 Days ▼ 11.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
19.43%
12-Months-Change
Fundamentals
Return on Equity
-39.70%
Trailing 12-Months
Asset Growth
-28.42%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc is a clinical-stage biotechnology company. It is focused on leveraging artificial intelligence machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from targeted oncology therapies. The firm's pipeline of development programs involves three small molecule drug candidates namely LP-100, LP-184, and LP-300.
---
LTRN Company Deck
---
LTRN Earnings Call
Q1 2024
0:00 / 0:00
---
LTRN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering LTRN
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-29.89%
reiterated a buy rating 11 months ago
Copying Michael King's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -29.89% per trade.
---